Results 191 to 200 of about 15,825 (259)

Is muscarinic receptor agonist effective and tolerant for schizophrenia? [PDF]

BMC Psychiatry
Guo X, Deng R, Lai J, Hu S.
europepmc   +1 more source

From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials. [PDF]

Int J Neuropsychopharmacol
Meyer JM, Kramer K, Vuocolo S, Kaul I, Miller AC.   +4 more
europepmc   +1 more source

Subcellular Redistribution of m2 Muscarinic Acetylcholine Receptors in Striatal InterneuronsIn Vivoafter Acute Cholinergic Stimulation

, 1998
Véronique Bernard, Ouahiba Laribi, Allan I. Levey, Bertrand Bloch   +3 more
openalex   +1 more source

Schizophrenia: Genetics, neurological mechanisms, and therapeutic approaches. [PDF]

Neural Regen Res
Lim DXE, Yeo SY, Chia ZYA, Fernandis AZ, Lee J, Chua JJE.   +5 more
europepmc   +1 more source

Herbal Amara extract induces gastric fundus relaxation via inhibition of the M2 muscarinic receptor. [PDF]

Neurogastroenterol Motil
Piqué-Borràs MR, Röhrl J, Künstle G.
europepmc   +1 more source

AiGPro: a multi-tasks model for profiling of GPCRs for agonist and antagonist. [PDF]

J Cheminform
Brahma R, Moon S, Shin JM, Cho KH.
europepmc   +1 more source

Discovery of Pre-Clinical Candidate <b>VU6008055</b>/<b>AF98943</b>: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M₄ Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust In Vivo Efficacy. [PDF]

ACS Chem Neurosci
Engers JL, Bollinger SR, Gregro AR, Capstick RA, Spearing PK, Long MF, Tarr JC, Watson KJ, Chang S, Luscombe VB, Rodriguez AL, Cho HP, Qi A, Niswender CM, Bubser M, Gould RW, Robb WH, Byun N, Gore J, Jones CK, Thomsen MS, Bridges TM, Boutaud O, Conn PJ, Engers DW, Lindsley CW, Temple KJ.   +26 more
europepmc   +1 more source

A sex-specific effect of M₄ muscarinic cholinergic autoreceptor deletion on locomotor stimulation by cocaine and scopolamine. [PDF]

Front Mol Neurosci
Berezovskaia A, Thomsen M, Fink-Jensen A, Wörtwein G.   +3 more
europepmc   +1 more source

Regulation of inflammaging. [PDF]

Bioinformation
Chiappelli F, Fotovat L, Khakshooy A, Oluwadara O, Penhaskashi J.   +4 more
europepmc   +1 more source

Control of cortical slow oscillations and epileptiform discharges with photoswitchable type 1 muscarinic ligands. [PDF]

PNAS Nexus
Sanchez-Sanchez JM, Riefolo F, Barbero-Castillo A, Sortino R, Agnetta L, Manasanch A, Matera C, Bosch M, Forcella M, Decker M, Gorostiza P, Sanchez-Vives MV.   +11 more
europepmc   +1 more source